MedTrace Logo

Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer

NCT04717154 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2026-01-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of 4 cycles of combinatory immunotherapy (ipilimumab and nivolumab), followed by monotherapy nivolumab in participants with immunogenic metastatic castration-resistant prostate cancer.

Conditions

  • Prostatic Neoplasms, Castration-Resistant

Interventions

BIOLOGICAL

Ipilimumab

4 courses of 1mg/kg q3w

BIOLOGICAL

Nivolumab

4 courses of 3mg/kg q3w, followed by maintenance flat dose (480mg, q4w, for 10 doses)

Sponsors & Collaborators

Principal Investigators

  • Niven Mehra, PhD · Radboud University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-19
Primary Completion
2024-08-15
Completion
2025-12-18

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04717154 on ClinicalTrials.gov